Biotechnology News and Research

RSS

Menarini Group signs licensing deal with Insilico for promising cancer treatment

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.

10 Jan 2025

Household dogs found to contribute to the spread of antibiotic-resistant Salmonella

Antibiotic-resistant Salmonella is a serious public health concern that has increased in recent years as the bacteria have developed ways to survive drugs.

9 Jan 2025

AI-designed drug shows promise for inflammatory bowel disease

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announces positive results from two Phase I studies in Australia and China of ISM5411, a novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico's Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory Bowel Disease (IBD).

8 Jan 2025

Key actions identified to improve post-acute care for TBI patients

A new systematic literature search identified the highest priority clinical actions aimed at improving post-acute care for non-hospitalized traumatic brain injury (TBI). The study is published in the peer-reviewed Journal of Neurotrauma.

7 Jan 2025

Researchers develop nanobody inhibitors to target Ebola virus

Ebola virus, one of the deadliest pathogens, has a fatality rate of about 50%, posing a serious threat to global health and safety.

7 Jan 2025

Insilico Medicine nominates ISM1745 as preclinical candidate for MTAP-deleted cancers

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced the nomination of ISM1745, a potentially best-in-class MTA cooperative PRMT5 inhibitor with AI-powered novel scaffold, as preclinical candidate (PCC) for the treatment of MTAP-deleted cancers.

2 Jan 2025

Freezing Point Osmometry in Life Science Applications

Osmometry is a method to determine a sample´s osmolality. This is the total number of osmotically active particles solved in a solution. These particles influence the colligative properties of the solution, which include the boiling and freezing point but also the vapor pressure for instance.

From KNAUER Wissenschaftliche Geräte GmbH 27 Dec 2024

New method detects human fecal contamination in water

The presence of human waste in sewage overflow or stormwater runoffs that ultimately find their way into rivers and lakes is a major public health hazard.

23 Dec 2024

Breakthrough in antigen recognition: TRACeR-I enhances immune targeting

Researchers describe TRACeR-I, a protein platform that can be used to engineer immune responses.

19 Dec 2024

Surgeons slow to adopt new biomaterials for bone defects

Two million bone transplants are performed worldwide yearly, including half a million in the United States alone. Yet, a QUT-led study has found surgeons are slow to adopt newly developed biomaterials or tissue-engineered solutions.

19 Dec 2024

Could microalgae fermentation create the superfoods of the future?

Microalgae fermentation unlocks sustainable and nutritious food production, offering bioactive peptides with antidiabetic properties but faces challenges in consumer acceptance.

18 Dec 2024

bit.bio raises $30 million led by M&G Investments

bit.bio, the global leader in cell programming technology, today announced the successful closing of a $30 million financing round led by M&G Investments, a leading international savings and investment company.

18 Dec 2024

Breakthrough microchip technology enables multi-disease detection

In a world grappling with a multitude of health threats - ranging from fast-spreading viruses to chronic diseases and drug-resistant bacteria - the need for quick, reliable, and easy-to-use home diagnostic tests has never been greater. Imagine a future where these tests can be done anywhere, by anyone, using a device as small and portable as your smartwatch.

16 Dec 2024

Novel drug holds promise for treating Duchenne muscular dystrophy

A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle degeneration.

16 Dec 2024

A new era of targeted therapy with antibody–drug conjugates

TBC

From Sino Biological Inc. 16 Dec 2024

New protein platform enhances cancer immunotherapy

Researchers from Children's Hospital of Philadelphia (CHOP) and Stanford University have revealed the molecular structure of TRACeR-I, a protein platform for reprogramming immune responses. A better understanding of its structure may help optimize designs for the platform, which can be used to develop cancer treatments by either directly modifying immune cells or by creating proteins that help immune cells locate cancer cells. The findings were published today by the journal Nature Biotechnology.

13 Dec 2024

Insilico Medicine gets first clinical milestone payment of $10 million for XL309

Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced that it has received the first clinical milestone payment of $10 million for XL309 (previously known as ISM3091) from Exelixis.

12 Dec 2024

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer - as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 mutation status - according to results from the phase III EMBER-3 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Scientists uncover genetic code driving tumor formation and spread

A group of scientists at VCU Massey Comprehensive Cancer Center has revealed a new genetic code that acts like a cancer ringleader, recruiting and deploying a gang of tumor cells to incite a biological turf war by invading healthy organs and overpowering the normal cells.

9 Dec 2024